Dexmedetomidine
دکسمدتومیدین
🧠 Nervous SystemAlpha-2 agonist (sedative)
Market / country: 🇺🇸 USA
Precedex (US)
🧮 Dose calculator
ICU and procedural sedation · Regimen source: FDA Precedex · 2.2, Table 1
- • Patients switched from another sedative may not need a load. Less invasive procedures (e.g. eye): 0.5 mcg/kg. Elderly and hepatic impairment: consider reduction. FDA Precedex · 2.2, Table 1
Enter age and weight.
🛡️ Safety & information
Warnings
- • Bradycardia, hypotension and sinus arrest; transient hypertension with loading; withdrawal on abrupt stop after prolonged use. FDA Precedex · 5
Formulations
- 4 mcg/mL ready-to-use (200 mcg/50 mL, 400 mcg/100 mL) — injection 🇺🇸 USA FDA Precedex · 3
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Precedex · 8.1
“Risk Summary Available data from published randomized controlled trials and case reports over several decades of use with intravenously administered dexmedetomidine during pregnancy have not identified a drug-associated risk of major birth defects and miscarriage; however, the reported exposures occurred after the …”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Precedex · 8.2
“Risk Summary Available published literature reports the presence of dexmedetomidine in human milk following intravenous administration (see Data ) .”
- 👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Precedex · 8.4
“Sedation for Non-Invasive Procedures The safety and efficacy of PRECEDEX have been established in pediatric patients 1 month to less than 18 years of age for sedation during non-invasive procedures.”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Precedex · 8.5
“In patients greater than 65 years of age, a higher incidence of bradycardia and hypotension was observed following administration of PRECEDEX [see Warnings and Precautions (5.2) ] .”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)NDA021038
- DailyMed (FDA label)FDA Precedex
- MedlinePlus (NIH)Dexmedetomidine InjectionDexmedetomidine Sublingual and Buccal
- WHO ATC/DDDN05CM18
- Darooyab (Iran)Dexmedetomidine
🇮🇷 Registered in Iran Darooyab · G-1265/Dexmedetomidine
Dosage forms with Iranian generic codes, per Darooyab.
- 17581 · DEXMEDETOMIDINE 100MCG/2ML VIAL · ویال دکسمدتومیدین ۱۰۰ میکروگرم / ۲ میلیلیتر
- 52044 · DEXMEDETOMIDINE (AS HYDROCHLORIDE) INJECTION PARENTERAL 4 ug/1mL 100 mL · فرآورده تزریقی دکسمدتومیدین (معادل هیدروکلراید) ۴ میکروگرم / ۱ میلیلیتر ۱۰۰ میلیلیتر
- 52043 · DEXMEDETOMIDINE (AS HYDROCHLORIDE) INJECTION PARENTERAL 4 ug/1mL 50 mL · فرآورده تزریقی دکسمدتومیدین (معادل هیدروکلراید) ۴ میکروگرم / ۱ میلیلیتر ۵۰ میلیلیتر
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Precedex · 3FDA Precedex · 2.2, Table 1FDA Precedex · 2.2FDA Precedex · 2.1FDA Precedex · 2.2, Table 2FDA Precedex · 5FDA Precedex · SPL approval / marketing categoryFDA Precedex · 8.1FDA Precedex · 8.2FDA Precedex · 8.4FDA Precedex · 8.5
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-1265/Dexmedetomidine
- Clinical review⚠ Unverified